Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entresto pediatric chronic heart failure specified drug-use survey
jRCT2031240443Active, not recruiting
- Sponsor
- Novartis
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of sacubitril + valsartan in chronic heart failure (CHF), sponsored by Novartis. Primary endpoint: Occurrence of events related to hypotension, hyperkalemia, renal impairment/renal failure, and dehydration. Started Nov 2024; status: active, not recruiting.
02
Drugs
sacubitril + valsartan
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on jRCT2031240443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240443.